These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 28520234)

  • 1. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors: A report of five cases.
    Yoshiji S; Murakami T; Harashima SI; Ko R; Kashima R; Yabe D; Ogura M; Doi K; Inagaki N
    J Diabetes Investig; 2018 Mar; 9(2):445-447. PubMed ID: 28520234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk heterogeneity of bullous pemphigoid among dipeptidyl peptidase-4 inhibitors: A population-based cohort study using Japanese Latter-Stage Elderly Healthcare Database.
    Harano Y; Mitamura Y; Jiang P; Fujita T; Babazono A
    J Diabetes Investig; 2023 Jun; 14(6):756-766. PubMed ID: 36897510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipeptidyl peptidase 4 inhibitors linked bullous pemphigoid in patients with type 2 diabetes mellitus: A series of 13 cases.
    Jha A; Misra A; Gupta R; Ghosh A; Tyagi K; Dutta K; Arora B; Durani S
    Diabetes Metab Syndr; 2020; 14(3):213-216. PubMed ID: 32172176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients.
    Kridin K; Bergman R
    JAMA Dermatol; 2018 Oct; 154(10):1152-1158. PubMed ID: 30090931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: the importance of the pharmacotherapeutic history.
    García-Gil MF; Lezcano Biosca V; García García M; Monte Serrano J; Aldea Manrique B
    Postgrad Med J; 2021 Jan; 97(1143):51-52. PubMed ID: 32198232
    [No Abstract]   [Full Text] [Related]  

  • 6. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid, likely triggered by scabies, in a hemodialysis patient with human leukocyte antigen-DQB1*03:01.
    Hibi A; Kasahara Y; Ishihara Y; Hata K; Hosokawa N; Nakagawa T
    CEN Case Rep; 2020 Aug; 9(3):189-194. PubMed ID: 31993957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical features of dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid in Japan: A nationwide retrospective observational study.
    Sugiyama S; Yamamoto T; Aoyama Y
    J Dermatol; 2022 Jul; 49(7):697-702. PubMed ID: 35478414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor - A case report.
    Karthik S; Joseph PE; Babu T
    J Postgrad Med; 2019; 65(4):244-246. PubMed ID: 31535624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case Report: Appearance of Various Disease-Specific Antibodies After the Onset of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.
    Iwamoto Y; Anno T; Koyama K; Kawasaki F; Kaku K; Tomoda K; Sugiyama S; Aoyama Y; Kaneto H
    Front Immunol; 2022; 13():843480. PubMed ID: 35309321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization.
    García-Díez I; Ivars-Lleó M; López-Aventín D; Ishii N; Hashimoto T; Iranzo P; Pujol RM; España A; Herrero-Gonzalez JE
    Int J Dermatol; 2018 Jul; 57(7):810-816. PubMed ID: 29682739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gliptin-induced bullous pemphigoid.
    Ganeva M; Gancheva T; Manuelyan K; Hristakieva E
    Int J Clin Pharmacol Ther; 2024 Feb; 62(2):89-95. PubMed ID: 38032147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical characteristics of bullous pemphigoid in elderly patients with type 2 diabetes mellitus: The association with the use of dipeptidyl peptidase-4 inhibitors].
    Kodera R; Chiba Y; Tamura Y; Miyazawa R; Tanei R; Mori S; Ito H; Araki A
    Nihon Ronen Igakkai Zasshi; 2019; 56(1):43-50. PubMed ID: 30760682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three Cases of Bullous Pemphigoid Associated with Dipeptidyl Peptidase-4 Inhibitors - One due to Linagliptin.
    Mendonça FM; Martín-Gutierrez FJ; Ríos-Martín JJ; Camacho-Martinez F
    Dermatology; 2016; 232(2):249-53. PubMed ID: 26820308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Risk of Bullous Pemphigoid With Initiation of Dipeptidyl Peptidase-4 Inhibitor vs Second-generation Sulfonylurea.
    Lee H; Chung HJ; Pawar A; Patorno E; Kim DH
    JAMA Dermatol; 2020 Oct; 156(10):1107-1114. PubMed ID: 32697283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid.
    Chijiwa C; Takeoka S; Kamata M; Tateishi M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Watanabe S; Tada Y
    J Dermatol; 2018 May; 45(5):596-599. PubMed ID: 29411416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipeptidyl peptidase-4 inhibitors and bullous pemphigoid: A systematic review and adjusted meta-analysis.
    Phan K; Charlton O; Smith SD
    Australas J Dermatol; 2020 Feb; 61(1):e15-e21. PubMed ID: 31215644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bullous Pemphigoid Associated with the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin in a Patient with Liver Cirrhosis Complicated with Rapidly Progressive Hepatocellular Carcinoma.
    Harada M; Yoneda A; Haruyama S; Yabuki K; Honma Y; Hiura M; Shibata M; Matsuoka H; Uchiwa Y
    Intern Med; 2017 Sep; 56(18):2471-2474. PubMed ID: 28824076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between dipeptidyl peptidase-4 inhibitors and increased risk for bullous pemphigoid within 3 months from first use: A 5-year population-based cohort study using the Japanese National Database.
    Kuwata H; Nishioka Y; Noda T; Kubo S; Myojin T; Higashino T; Takahashi Y; Ishii H; Imamura T
    J Diabetes Investig; 2022 Mar; 13(3):460-467. PubMed ID: 34559464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors. A case series and analysis of cases reported in the Spanish pharmacovigilance database.
    Reolid A; Muñoz-Aceituno E; Rodríguez-Jiménez P; González-Rojano E; Llamas-Velasco M; Fraga J; Daudén E
    Int J Dermatol; 2020 Feb; 59(2):197-206. PubMed ID: 31605541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.
    Tasanen K; Varpuluoma O; Nishie W
    Front Immunol; 2019; 10():1238. PubMed ID: 31275298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.